Pfizer’s Antibody Against IL-6 Shows Promise as Treatment for Lupus in Phase 2 Trial

Results from the Phase 2 BUTTERFLY trial conducted by Pfizer suggest that an antibody against the pro-inflammatory cytokine interleukin-6 (IL-6) may be a promising treatment for systemic lupus erythematosus (SLE). The study, “Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II…

IL-6 Antibody at Low Dose Can Ease Severe Flares in People with Active SLE, Study Reports

The monoclonal antibody against interleukin (IL)-6, called PF-04236921, was found to be efficient at reducing severe flares in systemic lupus erythematosus (SLE) patients — particularly in those with high disease activity — when administered at a 10 mg dose. The study, “Efficacy and safety of an interleukin 6 monoclonal antibody for…